+2.19%
Today
Loading 1D prices…
Company profile
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Redwood City, CA, United States
Employees
1
Fiscal year end
1231
CIK
1698530
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| XBIOXenetic Biosciences Inc. Common Stock | $9.1M | $3M | -90.07% | -$1.58 | -4.18% | Unrated |
| GDTCCytoMed Therapeutics Limited Ordinary Shares | $9.3M | — | — | -$0.39 | -1.84% | Unrated |
| SKYESkye Bioscience Inc. Common Stock | $9M | $0.00 | — | -$1.41 | -1.92% | Buy |
| ENSCEnsysce Biosciences Inc. Common Stock | $9.5M | $5.1M | -200.84% | -$3.98 | -5.62% | Unrated |
| BFRGBullfrog AI Holdings Inc. Common Stock | $8.8M | $116.7K | -5569.61% | -$0.63 | -2.06% | Hold |